Sign in
Sign up
Moby Premium

You are currently reading a preview of Moby Premium. To read this report in full. Please consider becoming a subscriber.

Start a free trial ➔
zoetis stock

This Biotech Stock Down 20% Is Ready To Reverse Course

health care Feb 16, 2022

This biotech stock has been completely ignored by most retail investors.

That is because their core products are focused on medicine and vaccinations for pets & livestock.

If you're not familiar with the market, the global animal health care market was last valued at $45 billion in 2020 and is expected to grow annually by 9% from 2022 to 2028.

The reason for this massive opportunity in growth is largely due to a significant rise in demand for protein based foods and food-borne diseases globally.

Pair that with COVID likely stemming from an animal, and the market opportunity for this unique sector within healthcare is much bigger than most investors realize.

And after reporting a very impressive earnings call yesterday, this stock looks ready to be one of the top healthcare stocks over the next few years.

So who are they?

What's our price target?

And what's the catalyst needed for this stock to blow up?